Individuals with potential exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
do not necessarily develop PCR or antibody positivity, suggesting that some …

Understanding the nature of immunity following mild/asymptomatic infection with SARS-CoV-2
is crucial to controlling the pandemic. We analyzed T cell and neutralizing antibody …

Background and Objective Despite the value of spinal cord stimulation (SCS) in treating
some patients with focal neuropathic pain, technological advances in stimulator design and …

Background SARS-CoV-2 serology is used to identify prior infection at individual and at
population level. Extended longitudinal studies with multi-timepoint sampling to evaluate …

Objectives Patients with established Parkinson's disease (PD) display differences in peripheral
blood markers of immune function, including leukocyte differential counts, compared with …

SARS‐CoV‐2, the causative agent of COVID‐19, typically manifests as a respiratory illness,
although extrapulmonary involvement, such as in the gastrointestinal tract and nervous …

Background Immune involvement is well-described in Parkinson’s disease (PD), including
an adaptive T lymphocyte response. Given the increasing prevalence of Parkinson’s disease …

Carbozyme, Inc. has developed a biomimetic technology that promises significant cost and
performance advantages over amine-scrubbing systems for the capture of CO 2 from …

To date, the clinical outcomes and survival rates for patients with glioblastoma (GB) remain
poor. A promising approach to disease‐modification involves local delivery of adjuvant …

Background: Most biomedical research has focused on sampling COVID-19 patients
presenting to hospital with advanced disease, with less focus on the asymptomatic or …